(Q35548189)

8 August 2017

1 reference

title

Effectiveness of drug therapies to treat or prevent respiratory syncytial virus infection-related morbidity (English)

1 reference

8 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14521489

16 March 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

16 March 2024

2

Anne Greenough

0 references

author name string

Simon Broughton

1

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

full work available at URL

8 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/14656566.4.10.1801

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Expert Opinion on Pharmacotherapy

16 March 2024

published in

1 reference

8 August 2017

4

1 reference

8 August 2017

1801-1808

1 reference

8 August 2017

10

1 reference

Intensive care course and outcome of patients infected with respiratory syncytial virus

8 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Acute respiratory distress syndrome caused by respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Short term effects of adrenaline in bronchiolitis: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Efficacy of nebulized epinephrine versus salbutamol in hospitalized infants with bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Efficacy of oral dexamethasone in outpatients with acute bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Respiratory syncytial virus bronchiolitis: a double-blind dexamethasone efficacy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Helium-oxygen mixture does not improve gas exchange in mechanically ventilated children with bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Heliox therapy in infants with acute bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

The effect of ribavirin to treat previously healthy infants admitted with acute bronchiolitis on acute and chronic respiratory morbidity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Early ribavarin treatment of bronchiolitis: effect on long-term respiratory morbidity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Respiratory syncytial virus immune globulin: decisions and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.10.1801

Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.

21 January 2018

5

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Respiratory status and allergy nine to 10 years after acute bronchiolitis

16 March 2024

6

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

The effect of nebulized epinephrine on respiratory mechanics and gas exchange in bronchiolitis

16 March 2024

9

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis

16 March 2024

10

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis

16 March 2024

12

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Dexamethasone in bronchiolitis: a randomised controlled trial

16 March 2024

16

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection

16 March 2024

20

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

16 March 2024

21

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Surfactant abnormalities in infants with severe viral bronchiolitis

16 March 2024

23

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Surfactant protein-A enhances uptake of respiratory syncytial virus by monocytes and U937 macrophages

16 March 2024

25

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Porcine-derived surfactant treatment of severe bronchiolitis.

16 March 2024

26

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Quantifying pulmonary hypertension in ventilated infants with bronchiolitis: a pilot study

16 March 2024

27

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Randomised controlled trial of budesonide for the prevention of post-bronchiolitis wheezing

16 March 2024

33

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

16 March 2024

40

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants

16 March 2024

41

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

16 March 2024

43

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid's high-risk children

16 March 2024

48

1 reference

https://api.crossref.org/works/10.1517/14656566.4.10.1801

16 March 2024

Identifiers

1 reference

8 August 2017

1 reference